Biomea Fusion reports Phase 1 weight loss data for oral GLP-1 drug

October 13, 2026 4:08 PM

Biomea Fusion, Inc. (Nasdaq: BMEA) released Phase 1 clinical trial results for BMF-650, an investigational oral small-molecule GLP-1 receptor agonist ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found